High Dose IL-2 in Combination With Anti-PD-1 to Overcome Anti-PD-1 Resistance in Metastatic Melanoma and Renal Cell Carcinoma
Part of paid clinical trials in La Jolla, California.
- Sponsor
- Gregory Daniels
- Study ID
- NCT03991130
- Phase
- PHASE2
- Status
- Terminated
Conditions
- Melanoma Stage Iv
- Renal Cell Carcinoma, Metastatic
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- IL-2 and Nivolumab — DRUGCourse length will be 35 days. Subjects will receive 480 mg IV of nivolumab on day 1 of the cycle. The patient will be admitted to UCSD Jacobs Medical center for standard HD IL-2 which will be administered every 8 hrs for up to 14 doses days 8-12 per institutional practice. The patient will be readmitted days 22-28 for HD IL-2 every 8 hrs for up to 14 doses. Nivolumab 480 mg IV will be administered day 35. Scans for response will occur 4 weeks after day 35 nivolumab dose and response will be determined by RECIST 1.1 to determine if the patient will receive the next course.
Study Details
The primary objective of this single arm phase 2 trial is to assess the response rate \[complete response (CR) + partial response (PR)\] of combined nivolumab and HD IL-2 in subjects with metastatic melanoma and renal cell carcinoma. Response will be performed after each course of nivolumab and IL-2 using RECIST 1.1. Patients will be treated for one course past best response for a maximum of 3 courses.
Key Dates
- Start date
- May 23, 2019
- Status verified
- Feb 2025
- Primary completion
- Jan 1, 2025
- Completion
- Jan 1, 2025
Study Design
- Enrollment
- 6 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: High Dose IL-2 and Nivolumab
Primary Outcome Measure
Overall Response Rate [ Time Frame: 3 years post treatment ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| UC San Diego Moores Cancer Center | La Jolla | California | 92093 | - |
Find similar trials in La Jolla, CA
By research site
Related Studies
- Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant MelanomaPHASE2 · Recruiting · University of California, San Francisco · La Jolla, California
- MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced MelanomaPHASE1/PHASE2 · Recruiting · Perspective Therapeutics · Orange, California
- A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid TumorsPHASE1/PHASE2 · Recruiting · Krystal Biotech, Inc. · Los Angeles, California
- Safety and Tolerability Study of GIM-531 in Advanced Solid TumorsPHASE1/PHASE2 · Recruiting · Georgiamune Inc · Scottsdale, Arizona